Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Decreased microglial activation in MS patients treated with glatiramer acetate.
Management of Fulminant Multiple Sclerosis With Rituximab: A Case Report.
Mechanical environment modulates biological properties of oligodendrocyte progenitor cells.
Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II).
Minocycline inhibits antigen processing for presentation to human T cells: additive inhibition with chloroquine at therapeutic concentrations.
Santhera to discontinue sale of Catena® in Canada
Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?
Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4 + T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis.
Better Prognosis of Multiple Sclerosis in Patients Who Experienced a Full-Term Pregnancy.
Epigenome-wide differences in pathology-free regions of multiple sclerosis-affected brains.
Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients.
Astaxanthin as a Potential Neuroprotective Agent for Neurological Diseases.
Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.
TGN1412: From Discovery to Disaster.
Copolymer-1 promotes neurogenesis and improves functional recovery after acute ischemic stroke in rats.
Fingolimod is a potential novel therapy for multiple sclerosis.
National Cancer Institute Search for Clinical Trials
FDA denies Teva Copaxone generic trials petition
Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.
[The first experience of the use the Russian Β-interferon-1b biosimilar (infibeta) in the daily practice of the Moscow Center of Multiple Sclerosis.]
Rituximab in paediatric onset multiple sclerosis: a case series.
Mitoxantrone-induced suicidal erythrocyte death.
Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis.
Genzyme submits applications to FDA and EMA for approval of LEMTRADA™ (alemtuzumab) for multiple sclerosis
European Medicines Agency

Pages